p1

Cambridge Healthtech Institute’s 16th Annual

Recombinant Protein Therapeutics

Fusion Proteins & Beyond

January 20-21, 2020

Part of the Protein Engineering & Development pipeline

Cambridge Healthtech Institute’s Recombinant Protein Therapeutics conference presents the latest developments in non-antibody therapeutics from international leaders. The conference focuses on the varying designs of fusion protein-based therapies and the latest data from R&D to post-approval, including case studies. By combining modular building blocks that can reach targets not accessible to antibodies, Fusion Protein Therapies possess advantages over antibody-based therapies; their customizable functionality translates into lower patient dosing, reduced production costs, and improved product homogeneity. This conference will demonstrate how these molecules are being engineered to form more efficacious therapeutics that offer specificity with enhanced stability and longer half-life.

Preliminary Agenda

ENGINEERING NEXT-GEN THERAPEUTIC FUSION PROTEINS

KEYNOTE PRESENTATION: From Cytokine Traps to Antibodies to Antibody-Protein Fusions

Aris N. Economides, PhD, Vice President, Research, Regeneron Pharmaceuticals, Inc.

Strategic and Technical Considerations on Designing, Manufacturing, and Using Complex Protein Therapeutics

Stefan Schmidt, PhD, MBA, COO and Head, Operations, BioAtrium AG

Novel Fc Platform Development and Applications for Fc-Fusion Proteins

Lu Shan, PhD, Scientist, Antibody Discovery and Protein Engineering, AstraZeneca plc

FUSION PROTEIN THERAPEUTICS AGAINST CANCER

T Cells Engineered with Immunomodulatory Fusion Proteins Enhance Adoptive Cell Therapy of Liquid and Solid Tumors

Shannon K. Oda, PhD, Research Associate, Philip D. Greenberg Laboratory, Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center

Preconditioning the Tumor Microenvironment to Enable Effective Immunotherapy Using Antibody Fusion Proteins

Alan Epstein, MD, PhD, Professor, Keck School of Medicine, University of Southern California (USC)

HERA-CD40L: A Unique Hexavalent CD40 Agonist for Cancer Immunotherapy

Katharina Billian-Frey, PhD, Senior Scientist, Drug Discovery, Apogenix AG

ALPN-202, a Novel Tri-Functional Immuno-Oncology Biologic

Mark Rixon, PhD, Senior Director, Protein Therapeutics, Alpine Immune Sciences

FIGHTING DISEASE WITH THERAPEUTIC FUSION PROTEINS

In vitro Evolution of a Vaccine-Elicited Antibody Identifies New Capabilities for Effective Fusion Peptide-Based HIV Neutralization

Bharat Madan, PhD, Postdoctoral Researcher, Pharmaceutical Chemistry, University of Kansas

Affibody Molecules in Psoriasis, Autoimmune Disease, and Cancer: From Lab Bench to Patient Outcomes

Joachim Feldswich, PhD, Director, Preclinical Development, Affibody AB



* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/08/23
Sponsor updated




2020 Conferences & Training Seminars